Shield Therapeutics Share Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Shield Therapeutics stock.
View analyst ratings for Shield Therapeutics or view top-rated stocks.

Wall Street analysts have given Shield Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Shield Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Shield Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 17th 2021.
View our earnings forecast for Shield Therapeutics.

Shield Therapeutics' stock was trading at GBX 121.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STX stock has decreased by 63.0% and is now trading at GBX 45.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Shield Therapeutics include Amryt Pharma (AMYT), The Supreme Cannabis (FIRE), ICC Labs (ICC), The Green Organic Dutchman (TGOD), ESSA Pharma (EPI), Venture Life Group (VLG), Diurnal Group (DNL), WeedMD (WMD), Delta 9 Cannabis (NINE), Acerus Pharmaceuticals (ASP), Science in Sport (SIS), The Flowr (FLWR), BioSyent (RX), Medexus Pharmaceuticals (MDP) and Viridium Pacific Group (VIR).
View all of STX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and SkinBioTherapeutics (SBTX).

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

One share of STX stock can currently be purchased for approximately GBX 45.

Shield Therapeutics has a market capitalization of £97.13 million and generates £9.21 million in revenue each year.

Shield Therapeutics employs 20 workers across the globe.

The official website for Shield Therapeutics is www.shieldtherapeutics.com.

Shield Therapeutics is headquartered at 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom.

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.